- Home
- PYN vs BNR Comparison
PYN vs BNR Comparison
Compare PYN & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYN
- BNR
- Stock Information
- Founded
- PYN 2002
- BNR 2014
- Country
- PYN United States
- BNR China
- Employees
- PYN N/A
- BNR N/A
- Industry
- PYN Investment Managers
- BNR Medical Specialities
- Sector
- PYN Finance
- BNR Health Care
- Exchange
- PYN Nasdaq
- BNR Nasdaq
- Market Cap
- PYN 30.4M
- BNR 29.1M
- IPO Year
- PYN N/A
- BNR 2020
- Fundamental
- Price
- PYN $5.26
- BNR $2.90
- Analyst Decision
- PYN
- BNR
- Analyst Count
- PYN 0
- BNR 0
- Target Price
- PYN N/A
- BNR N/A
- AVG Volume (30 Days)
- PYN 19.9K
- BNR 34.9K
- Earning Date
- PYN 01-01-0001
- BNR 06-17-2025
- Dividend Yield
- PYN 5.07%
- BNR N/A
- EPS Growth
- PYN N/A
- BNR N/A
- EPS
- PYN N/A
- BNR N/A
- Revenue
- PYN N/A
- BNR $72,112,038.00
- Revenue This Year
- PYN N/A
- BNR $136.32
- Revenue Next Year
- PYN N/A
- BNR N/A
- P/E Ratio
- PYN N/A
- BNR N/A
- Revenue Growth
- PYN N/A
- BNR N/A
- 52 Week Low
- PYN $4.84
- BNR $2.18
- 52 Week High
- PYN $6.60
- BNR $7.90
- Technical
- Relative Strength Index (RSI)
- PYN 39.31
- BNR 45.30
- Support Level
- PYN $5.23
- BNR $2.80
- Resistance Level
- PYN $5.31
- BNR $3.29
- Average True Range (ATR)
- PYN 0.21
- BNR 0.33
- MACD
- PYN -0.00
- BNR 0.02
- Stochastic Oscillator
- PYN 3.77
- BNR 42.89
About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest
PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.